Canterbury DHB

Context

Assessment of Severity and Prognosis

In This Section

Assessment of Severity

Prognosis

Assessment of Severity

This varies to some extent in the published literature. The following criteria are commonly used:

Severe AA:

Note: Very severe AA - the above criteria apply but with a neutrophil count < 0.2 x109/L.

Moderate AA:

Prognosis

When only supportive care is given, AA carries a mortality rate of 80-90%.

Following ATG and cyclosporin variable results have been reported from a median survival of 6 years to a 58% survival at 11 years.

Long-term, MDS, AML, and PNH may occur in 5-10% of patients who respond to immunosuppression.

By contrast, a stem cell transplant is curative, with long term survival between 60% and 90%.

Those patients under 16 do best with an allograft and the results become less good over the age of 25.

About this Canterbury DHB document (4923):

Document Owner:

Mark Smith (see Who's Who)

Issue Date:

August 2017

Next Review:

August 2019

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 4923